• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Capricor Therapeutics Inc.

    10/17/23 4:05:13 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CAPR alert in real time by email
    SC 13G 1 tm2328179d1_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.     )*

     

    Capricor Therapeutics, Inc.
    (Name of Issuer)

     

    Common Stock
    (Title of Class of Securities)
     
    14070B309
    (CUSIP Number)

     

    October 3, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)
         
      x Rule 13d-1(c)
         
      ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 14070B309 13G Page 1 of 5 Pages

    (l)

    Names of Reporting Persons.

     

    Nippon Shinyaku Co., Ltd.

    (2)

    Check the Appropriate Box if a Member of a Group

     

    (a) ¨

    (b) ¨

    (3)

    SEC Use Only

     

     

    (4)

    Citizenship or Place of Organization

     

    Japan

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    (5)

    Sole Voting Power

     

    2,145,922

    (6)

    Shared Voting Power

     

    0

    (7)

    Sole Dispositive Power

     

    2,145,922

    (8)

    Shared Dispositive Power

     

    0

    (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,145,922

    (10)

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    (11)

    Percent of Class Represented by Amount in Row (9)

     

    6.97%*

    (12)

    Type of Reporting Person

     

    FI

     

    * Calculated based on 30,790,691 shares outstanding of the Issuer.

     

     

     

     

    Item l(a). Name of Issuer:

     

    Capricor Therapeutics, Inc.

     

    Item l(b). Address of Issuer’s Principal Executive Offices:

     

    840 Wilshire Blvd., 2nd Floor, Beverly Hills, California 90211

     

    Item 2(a). Name of Person Filing:

     

    Nippon Shinyaku Co., Ltd.

     

    Item 2(b). Principal Business Offices or, if None, Residence:

     

    14, Nishinosho-Monguchi-cho, Kisshoin, Minami-ku,

    Kyoto 601-8550, Japan

     

    Item 2(c). Citizenship:

     

    The Reporting Person is organized under the laws of Japan.

     

    Item 2(d). Title of Class of Securities:

     

    Common Stock, par value $0.001

     

    Item 2(e). CUSIP Number:

     

    14070B309

     

    Item 3. If this statement is filed pursuant to 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e) ¨ An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);

     

    (g) ¨ A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

    (j) ¨ a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);

     

    (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K),

     

     

     

     

    Item 4. Ownership.

     

    (a) Amount beneficially owned:
       
      2,145,922
       
    (b) Percent of class:
       
      6.97%*
       
    (c) Number of shares as to which such person has:
       
    (i) Sole power to vote or to direct the vote:
       
      2,145,922
       
    (ii) Shared power to vote or to direct the vote:
       
      -
       
    (iii) Sole power to dispose or to direct the disposition of:
       
      2,145,922
       
    (iv) Shared power to dispose or to direct the disposition of:
       
      -

     

    5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

     

    6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable

     

    7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    N/A

     

    8. Identification and Classification of Members of the Group.

     

    N/A

     

    9. Notice of Dissolution of Group.

     

    N/A

     

    10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

     

    * Calculated based on 30,790,691 shares outstanding of the Issuer.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Date: October 17, 2023
       
      By: /s/ Takanori Edamitsu
       
      Name and Title: Takanori Edamitsu, Director, Business Management & Sustainability

     

     

     

    Get the next $CAPR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAPR

    DatePrice TargetRatingAnalyst
    6/30/2025$20.00Buy
    Alliance Global Partners
    6/26/2025$21.00Buy
    B. Riley Securities
    5/20/2025$31.00Buy
    Roth Capital
    10/21/2024$35.00Overweight
    Piper Sandler
    5/17/2024$14.00Outperform
    Oppenheimer
    1/5/2024$8.00Overweight
    Cantor Fitzgerald
    10/26/2022$15.00Buy
    Ladenburg Thalmann
    1/31/2022$14.00 → $18.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CAPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine

    First-in-human trial of Capricor's StealthX™ vaccine initiated under HHS's Project NextGenTrial conducted and funded by the National Institute of Allergy and Infectious Diseases (NIAID) SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the first subjects have been dosed in a Phase 1 clinical trial evaluating its StealthX™ exosome-based vaccine. The study, funded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) under the U.S. Department of Health and Human Services' Project Nex

    8/18/25 9:00:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approvalCapricor seeks to resubmit its BLA based on its existing dataset, with HOPE-3 data (expected in Q4 2025) potentially serving as supportive and confirmatory evidence, pending regulatory guidanceAll 483 observations noted in the Pre-License Inspection have been resolved and accepted by the FDAFDA clears IND for StealthX™ exosome-based vaccine; NIAID has initiated the Phase 1 clinical trial Cash balance of approximately $123 million expected to support planned operations into the fourth quarter of 2026 Capricor will host a conference call and webcast today at 4:30 p.m. ET SAN DIEGO, Aug. 1

    8/11/25 4:05:00 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

    SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the regulatory path for its Biologics License Application (BLA) for Deramiocel, the Company's lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). To accommodate this meeting, the Company has rescheduled the release of its financial results for the second quarter ended June 30, 2025, to Monday, August 11, 2025,

    8/8/25 8:30:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Nippon Shinyaku Co Ltd bought $14,999,998 worth of shares (2,798,507 units at $5.36), increasing direct ownership by 65% to 7,090,351 units (SEC Form 4)

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    9/24/24 4:01:08 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Musket David B bought $1,128 worth of shares (410 units at $2.75), increasing direct ownership by 1% to 31,536 units (SEC Form 4)

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    10/13/23 1:59:57 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collier Earl M Jr bought $28,300 worth of shares (10,000 units at $2.83), increasing direct ownership by 59% to 26,856 units (SEC Form 4)

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    10/12/23 9:15:07 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Marban Linda exercised 25,000 shares at a strike of $1.39 and disposed of 12,500 shares, increasing direct ownership by 6% to 211,104 units (SEC Form 4)

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    3/5/25 5:00:13 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Bergmann Anthony exercised 2,500 shares at a strike of $1.39, increasing direct ownership by 44% to 8,223 units (SEC Form 4)

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    3/4/25 7:00:17 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Litvack Frank exercised 25,000 shares at a strike of $1.39 and covered exercise/tax liability with 2,543 shares, increasing direct ownership by 21% to 129,839 units (SEC Form 4)

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    3/4/25 7:00:13 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    SEC Filings

    View All

    SEC Form 10-Q filed by Capricor Therapeutics Inc.

    10-Q - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

    8/11/25 5:25:49 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

    8/11/25 4:06:21 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Capricor Therapeutics Inc.

    SCHEDULE 13G - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

    7/29/25 11:23:11 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Capricor Therapeutics with a new price target

    Alliance Global Partners initiated coverage of Capricor Therapeutics with a rating of Buy and set a new price target of $20.00

    6/30/25 7:58:51 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Capricor Therapeutics with a new price target

    B. Riley Securities initiated coverage of Capricor Therapeutics with a rating of Buy and set a new price target of $21.00

    6/26/25 8:09:16 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Capricor Therapeutics with a new price target

    Roth Capital initiated coverage of Capricor Therapeutics with a rating of Buy and set a new price target of $31.00

    5/20/25 8:11:35 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    Leadership Updates

    Live Leadership Updates

    View All

    Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer

    SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the appointment of Michael Binks, M.D., as Chief Medical Officer, effective immediately. Dr. Binks brings 25 years of experience leading global clinical development and translational research across the pharmaceutical and biotechnology sectors. "Michael is an outstanding addition to Capricor's leadership team as we advance deramiocel toward potential commercialization for the treatment of Duchenne muscular dystrophy (DMD) and explore future pipeline expansion opportunities," said Linda

    5/13/25 9:00:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

    SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today, July 1, 2024. "We are thrilled to be joining the Russell 2000® Index, a testament to our Company's progress across our pipeline marked by significant advancements in our lead program for the treatment of Duchenne muscular dystrophy," said Linda Marbán, Ph.D., Capricor's chief executive officer. "This milestone reflects Ca

    7/1/24 9:00:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

    SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company has appointed Michael Kelliher to its Board of Directors, effective immediately. Mr. Kelliher, Group Vice President of M&A and Business Development at Horizon Therapeutics, brings to Capricor extensive expertise in business development, strategy, finance and operational leadership across the life sciences industry. "It is a pleasure to welcome Mike to our Board of Directors, who has an extraor

    9/6/23 9:00:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    Financials

    Live finance-specific insights

    View All

    Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approvalCapricor seeks to resubmit its BLA based on its existing dataset, with HOPE-3 data (expected in Q4 2025) potentially serving as supportive and confirmatory evidence, pending regulatory guidanceAll 483 observations noted in the Pre-License Inspection have been resolved and accepted by the FDAFDA clears IND for StealthX™ exosome-based vaccine; NIAID has initiated the Phase 1 clinical trial Cash balance of approximately $123 million expected to support planned operations into the fourth quarter of 2026 Capricor will host a conference call and webcast today at 4:30 p.m. ET SAN DIEGO, Aug. 1

    8/11/25 4:05:00 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

    SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the regulatory path for its Biologics License Application (BLA) for Deramiocel, the Company's lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). To accommodate this meeting, the Company has rescheduled the release of its financial results for the second quarter ended June 30, 2025, to Monday, August 11, 2025,

    8/8/25 8:30:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

    SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the market close on Wednesday, August 13, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on the same day. Title:Capricor Therapeutics Second Quarter 2025 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Wednesday, August 13, 2025Time:4:30 p.m. ETCall Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Confere

    8/6/25 9:00:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Capricor Therapeutics Inc.

    SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

    11/8/24 9:00:23 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Capricor Therapeutics Inc.

    SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

    9/24/24 4:03:22 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Capricor Therapeutics Inc.

    SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

    8/23/24 4:01:31 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care